Trials / Terminated
TerminatedNCT04697056
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Subjects With Ichthyosis
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Vanda Pharmaceuticals · Industry
- Sex
- All
- Age
- 12 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and Safety of imsidolimab in Participants with Ichthyosis
Detailed description
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of imsidolimab compared with placebo in adolescent and adult participants with ichthyosis. This study will also characterize the pharmacokinetic (PK) profile of imsidolimab and explore the immune response to imsidolimab in participants with ichthyosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imsidolimab | Humanized Monoclonal Antibody |
| BIOLOGICAL | placebo | placebo |
Timeline
- Start date
- 2021-01-25
- Primary completion
- 2021-11-19
- Completion
- 2021-11-19
- First posted
- 2021-01-06
- Last updated
- 2025-09-16
- Results posted
- 2023-03-02
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04697056. Inclusion in this directory is not an endorsement.